Casgevy's $2.2M Gene Therapy Expands to Ages 2+, Shifting Care

CRISPR Therapeutics enters the final four months of 2026 at a potentially pivotal juncture. The company’s only approved product, Casgevy, has received a label expansion that could broaden its addressable patient population, and the company is expected to report clinical data readouts that could validate its broader gene-editing pipeline. This comes as CRSP shares have slightly underperformed the broader market through early September 2026, setting up a catalyst-rich period for the stock. Casgevy, developed in collaboration with Vertex Pharmaceuticals, earned FDA approval in 2023 for transfusion-dependent beta-thalassemia (TDT) and sickle cell disease (SCD) in patients aged 12 and older. It was a landmark as the first CRISPR-based therapy to reach market, but commercial uptake has been slow. A single treatment course costs $2.2 million in the U.S., and the ex vivo process—collecting a patient’s cells, editing them in a lab, and reinfusing them—takes months. Those two factors, combined with the original age restriction, limited the initial addressable market. The first catalyst is the label expansion. Earlier in 2026, the FDA expanded Casgevy’s indication to include patients as young as two years old. This matters clinically because intervening earlier can prevent the cumulative organ damage and complications that SCD and TDT cause over time. From a commercial standpoint, it expands the eligible patient pool to younger children, a population where disease-modifying therapy has historically been limited. While the company and Vertex are unlikely to see an immediate revenue inflection before year-end, increased demand and improved third-party coverage following the label expansion could be enough to move the stock. The second catalyst is clinical data readouts. CRISPR Therapeutics is advancing a pipeline of gene-editing candidates beyond Casgevy, and any positive data could de-risk the platform and support a higher valuation. Gene editing peers have struggled to demonstrate durable efficacy outside rare hematologic conditions, so upcoming data will be scrutinized for evidence that CRISPR’s approach can translate to other indications. The timing of these readouts in the final four months of 2026 gives investors discrete, binary events to trade around. Still, downside risk is substantial. Ex vivo gene-editing therapies remain logistically complex, requiring specialized cell-processing facilities and long patient journeys. Even with a broader label, the $2.2 million price tag will continue to test payer willingness to reimburse. Furthermore, if the clinical readouts disappoint or show safety concerns, the stock could decline sharply, particularly given that it has already lagged the market this year. Looking ahead, the next four months will be defined by execution on Casgevy’s commercial ramp and the credibility of CRISPR Therapeutics’ pipeline data. Investors should watch for signs of third-party coverage expansion, commentary on patient starts, and the specific clinical milestones the company highlights. The stock may be volatile around these catalysts, but for risk-tolerant investors, the final stretch of 2026 offers a compelling, if speculative, setup.